NAV

Buthiazide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Buthiazide is a diuretic indicated in the treatment of edema caused by congestive heart failure, as well as hepatic and renal diseases.

Generic Name
Buthiazide
DrugBank Accession Number
DB15861
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 353.84
Monoisotopic: 353.0270761
Chemical Formula
C11H16ClN3O4S2
Synonyms
  • Buthiazide
  • Butizida
  • Butizide
  • Butizidum
  • Isobutylhydrochlorothiazide
External IDs
  • S 3500
  • SU 6187
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to treatEdemaCombination Product in combination with: Canrenoic acid (DB09015)•••••••••••••••••••••••
Used in combination to treatEdemaCombination Product in combination with: Canrenoic acid (DB09015)•••••••••••••••••••••••
Used in combination to treatEdemaCombination Product in combination with: Canrenoic acid (DB09015)•••••••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbacavirButhiazide may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.
AbaloparatideAbaloparatide may increase the hypotensive activities of Buthiazide.
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Buthiazide.
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Buthiazide.
AcebutololThe therapeutic efficacy of Acebutolol can be increased when used in combination with Buthiazide.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Eunephran
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Aldactone - Saltucin forte - HartkapselnButhiazide (10 mg) + Spironolactone (100 mg)CapsuleOralHerbrand Pharma Chemicals Gmb H1979-05-11Not applicableAustria flag
KADIURButhiazide (5 MG) + Potassium canrenoate (50 MG)Tablet, coatedOralNeopharmed Gentili S.P.A.2014-07-08Not applicableItaly flag
KADIURButhiazide (5 MG) + Potassium canrenoate (50 MG)Tablet, coatedOralNeopharmed Gentili S.P.A.2014-07-08Not applicableItaly flag
KADIURButhiazide (5 mg) + Potassium canrenoate (50 mg)TabletOralNeopharmed Gentili S.P.A.2014-07-082021-04-20Italy flag

Categories

ATC Codes
C03EA14 — Butizide and potassium-sparing agents
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
W00SSD35VW
CAS number
2043-38-1
InChI Key
HGBFRHCDYZJRAO-UHFFFAOYSA-N
InChI
InChI=1S/C11H16ClN3O4S2/c1-6(2)3-11-14-8-4-7(12)9(20(13,16)17)5-10(8)21(18,19)15-11/h4-6,11,14-15H,3H2,1-2H3,(H2,13,16,17)
IUPAC Name
6-chloro-3-(2-methylpropyl)-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
SMILES
CC(C)CC1NC2=C(C=C(C(Cl)=C2)S(N)(=O)=O)S(=O)(=O)N1

References

General References
  1. AIFA Product Information: KADIUR (Buthiazide and Potassium canrenoate) tablet [Link]
ChemSpider
15442
RxNav
19882
ChEBI
135492
ChEMBL
CHEMBL2104197
Wikipedia
Butizide

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CapsuleOral
TabletOral
Tablet, coatedOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.498 mg/mLALOGPS
logP0.68ALOGPS
logP1.02Chemaxon
logS-2.8ALOGPS
pKa (Strongest Acidic)9.07Chemaxon
pKa (Strongest Basic)-2.6Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area118.36 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity81.57 m3·mol-1Chemaxon
Polarizability33.75 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0009000000-18d45777cee12cce1196
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0019000000-efb054d8eab547887a6f
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0r00-0019000000-888c687e4e7fbb9f0241
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0019000000-3617e8a196357ed3afaa
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0gbl-9481000000-482ffb4a4c2d090bd01b
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-01u0-9010000000-919937acb9a02f299016
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-172.47206
predicted
DeepCCS 1.0 (2019)
[M+H]+175.35211
predicted
DeepCCS 1.0 (2019)
[M+Na]+183.81773
predicted
DeepCCS 1.0 (2019)

Drug created at September 17, 2020 22:04 / Updated at May 14, 2021 01:08